Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis

Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis

Background and objectives: Chronic kidney disease (CKD) is a serious health problem with an increasing clinical, social and economic impact in advanced stages. Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor that reduces the risk of CKD progression, in addition to provide cardiovascular...

Full description

Saved in:
Bibliographic Details
Main Authors: Juan Francisco Navarro-González, Alberto Ortiz, Ana Cebrián Cuenca, Lluís Segú, Belén Pimentel, Unai Aranda, Blanca Lopez-Chicheri, Margarita Capel, Elisenda Pomares Mallol, Christian Caudron, Juan José García Sánchez, Roberto Alcázar Arroyo
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Nefrología (English Edition)
Subjects:
Compensación de costes
Dapagliflozina
Enfermedad renal crónica
Evaluación económica
Online Access:http://www.sciencedirect.com/science/article/pii/S2013251424002232
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2013251424002232

Similar Items